September 2024 Optum Rx Drug Pipeline Insights Report
Something old for COPD and something new for schizophrenia – each offers a unique approach for cases that have failed other treatments.
The September edition of the Drug Pipeline Insights Report showcases:
- A new mechanism for schizophrenia with reduced side effects
- An expanded drug indication for top 10 seller, Dupixent: COPD
Related healthcare insights
Guide
Read the most recent quarterly reports on new drugs coming down the pipeline.
Guide
New treatments for NASH, schizophrenia and more are on the way.
Article
See which trends to consider when assessing the pharmacy benefit, which new drugs may be flying under the radar and what's coming.